ArticleJournal of surgical oncology2026
National Trends in the Use of Palliative Therapy in Stage IV Rectal Cancer in the United States.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPalliative-intent therapies are a key component in the management of metastatic rectal cancer; however, contemporary national trends and disparities in their utilization remain incompletely characterized.
methodsA retrospective cohort study was conducted using the National Cancer Database (NCDB) from 2012 to 2023. Adult patients with stage IV rectal adenocarcinoma were included. Palliative therapy was defined using the NCDB variable indicating treatment administered with non-curative intent. Temporal trends were evaluated overall and stratified by facility type and median household income. Multivariable logistic regression was performed to identify independent predictors of palliative therapy utilization.
resultsA total of 43 443 patients were included, of whom 8931 (20.6%) received palliative-intent therapy. Utilization increased significantly over time, from 16.2% in 2012 to 25.6% in 2023 (p < 0.001). Systemic therapy was the most frequently used modality and increased over time, while surgical palliation declined substantially. Immunotherapy use rose markedly in later years. Palliative therapy utilization increased across all facility types. Across all income strata, utilization also increased, with the most pronounced rise among patients from lower-income areas. On multivariable analysis, lower income (OR 1.82, 95% CI 1.21-2.74), brain metastases (OR 5.75, 95% CI 1.76-18.70), and immunotherapy use (OR 1.65, 95% CI 1.24-2.21) were independently associated with increased odds of receiving palliative therapy, whereas primary tumor resection was associated with reduced utilization (OR 0.45, 95% CI 0.32-0.61).
conclusionIn this large national cohort, palliative therapy utilization increased modestly over time, with a shift from surgical to systemic approaches. These patterns, observed across diverse healthcare settings and socioeconomic groups, reflect the evolving integration of palliative-intent treatment in the modern management of metastatic rectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.